Antibodies in Repeated Influenza Vaccination (ARIVA) Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04059991

Acronym

ARIVA

Enrollment

150

Registered

2019-08-16

Start date

2017-11-01

Completion date

2021-03-31

Last updated

2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccine Response Impaired

Brief summary

Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine design. The current influenza vaccination strategy of yearly vaccination with adapted strains aims to maximally diversify the antibody immune response to prevent viral escape. There is, however, growing evidence, that repeated vaccination with very similar viral proteins might limit, instead of broaden, diversification and thereby reduce vaccine efficacy. The ARIVA Study prospectively studies the immunological impact of repeated influenza vaccination on viral variant recognition and antibody responses in healthy subjects cross-sectionally and over three consecutive vaccination seasons.

Interventions

BIOLOGICALInfluenza Vaccination

Only subjects vaccinated against influenza will be enrolled. The study itself is observational

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* influenza vaccination (QIIV) independent of the study * age \>18 yo

Exclusion criteria

* no vaccination * current acute illness

Design outcomes

Primary

Measure	Time frame	Description
Influenza specific Antibody Responses	Change between baseline and 28 days post-vaccination will be compared	Hemagglutination titers against different H3N2 Influenza strains will be measured and compared between study subjects stratified by number of previous vaccinations

Secondary

Measure	Time frame	Description
Plasmablast generation	Day 7 post-vaccination	Frequency of plasmablasts in the peripheral blood will be assessed and compared between study subjects stratified by number of previous vaccinations
BCR Repertoire composition	Cross sectional comparison of the BCR repertoire characteristics day 0 and day 28	Sorted B cell subsets will be sequenced to define the BCR repertoire. Subjects will be compared stratified by vaccination status

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026